Obesity is currently a growing public health concern (134) and as weight loss improves many obesity-related complications (135), there is a great deal of interest in developing weight-loss drugs
published a landmark study in Nature Communications showing that MOTS-c treatment could double treadmill running capacity in old mice, restoring physical performance to levels seen in animals a fraction of their age.2 Meanwhile, orthopedic surgeons were cataloguing a parallel revolution: synthetic peptides like BPC-157, originally derived from a protective protein in human gastric juice, were showing preclinical promise in accelerating tendon, ligament, and muscle repairthe very tissues endurance athletes stress on an almost daily basis.3 The peptide therapeutics market is no longer a niche curiosity
However, neurotrophins have had little success in clinical trials directed at neurodegenerative diseases due to their poor pharmokinetic profile and large molecular weight that significantly impedes penetration of the BBB [61,62]
ISGlobal received support from the grant CEX2018-000806-S funded by MCIN/AEI/ support from the Generalitat de Catalunya through the CERCA Program, and support from the Unitaid under the BOHEMIA grant
